OMIC Stock Overview
Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology for researchers and clinicians to advance science and medicine.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Singular Genomics Systems, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.38 |
| 52 Week High | US$1.21 |
| 52 Week Low | US$0.31 |
| Beta | 1.4 |
| 1 Month Change | -24.60% |
| 3 Month Change | -9.18% |
| 1 Year Change | -65.09% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -98.53% |
Recent News & Updates
Shareholder Returns
| OMIC | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -22.9% | -2.5% | -1.7% |
| 1Y | -65.1% | -4.1% | 22.4% |
Return vs Industry: OMIC underperformed the US Life Sciences industry which returned -4.1% over the past year.
Return vs Market: OMIC underperformed the US Market which returned 22.4% over the past year.
Price Volatility
| OMIC volatility | |
|---|---|
| OMIC Average Weekly Movement | 11.4% |
| Life Sciences Industry Average Movement | 7.1% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: OMIC's share price has been volatile over the past 3 months.
Volatility Over Time: OMIC's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 255 | Drew Spaventa | singulargenomics.com |
Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables for applications comprising single cell gene expression and proteomics, in situ RNA sequencing, and spatial RNA and proteomics applications for tissue. Singular Genomics Systems, Inc. was incorporated in 2016 and is based in San Diego, California.
Singular Genomics Systems, Inc. Fundamentals Summary
| OMIC fundamental statistics | |
|---|---|
| Market cap | US$31.63m |
| Earnings (TTM) | -US$94.82m |
| Revenue (TTM) | US$2.91m |
9.6x
P/S Ratio-0.3x
P/E RatioIs OMIC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OMIC income statement (TTM) | |
|---|---|
| Revenue | US$2.91m |
| Cost of Revenue | US$3.47m |
| Gross Profit | -US$558.00k |
| Other Expenses | US$94.26m |
| Earnings | -US$94.82m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.28 |
| Gross Margin | -19.17% |
| Net Profit Margin | -3,257.30% |
| Debt/Equity Ratio | 5.0% |
How did OMIC perform over the long term?
See historical performance and comparison